Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Multiple Sclerosis

Therapeutic area intelligence for Multiple Sclerosis with 18 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
18
Catalysts
0
Companies
5

Companies

Alembic Pharmaceuticals →
Novartis →
Roche →
Sandoz →
Teva →

Assets

Alembic →
Copaxone →
Corticosteroids →
CYCLE →
Dalfampridine →
FDA →
Innovative →
MAVENCLAD →
MAYZENT →
OCREVUS →
Orelabrutinib →
remibrutinib →
TYRUKO →
YTB323 →

Recent signals(18)

StrategyJuly 30, 2026

FDA Approves Fingolimod Hydrochloride Application by Alembic

The FDA has granted approval for the ANDA207974 application for Fingolimod Hydrochloride submitted by Alembic.

RegulatoryJuly 29, 2026

FDA Accepts Supplemental Application for TYRUKO (Natalizumab-SZTN)

The FDA has accepted a supplemental application for TYRUKO, a biosimilar of natalizumab.

RegulatoryJuly 28, 2026

FDA Accepts Supplement for Dalfampridine by Accord Healthcare

The FDA has accepted a supplemental application for Dalfampridine submitted by Accord Healthcare.

ClinicalJuly 22, 2026

Peer Support Study Aims to Enhance Adherence in MS Patients

A pilot study is underway to evaluate the effect of peer support on therapeutic adherence in patients with relapsing-remitting multiple sclerosis.

RegulatoryJuly 17, 2026

FDA Accepts Supplement for MAVENCLAD by EMD Serono

The FDA has accepted a supplemental application for MAVENCLAD (cladribine) from EMD Serono.

ClinicalJuly 14, 2026

Novartis Evaluates Remibrutinib for Secondary Progressive Multiple Sclerosis

Novartis is conducting a study to assess the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis.

RegulatoryJuly 14, 2026

FDA Grants Priority Review for OCREVUS Supplemental Application

The FDA has granted priority review for the supplemental application of OCREVUS (ocrelizumab) submitted by Genentech.

RegulatoryJuly 9, 2026

FDA Accepts Supplemental Application for MAYZENT (Siponimod) by Novartis

The FDA has accepted a supplemental application for MAYZENT (siponimod) submitted by Novartis.

RegulatoryJuly 8, 2026

FDA Approves Supplemental Application for TASCENSO ODT

The FDA has approved a supplemental application for TASCENSO ODT, containing Fingolimod Lauryl Sulfate.

RegulatoryJuly 8, 2026

FDA Accepts Supplemental Application for Copaxone (Glatiramer Acetate)

The FDA has accepted a supplemental application for Copaxone, a treatment for multiple sclerosis.

StrategyJuly 6, 2026

Alembic's ANDA207974 for Fingolimod Hydrochloride Receives Approval

The FDA has approved Alembic's Abbreviated New Drug Application (ANDA) for Fingolimod Hydrochloride.

StrategyJuly 5, 2026

FDA Submission Update for Dalfampridine by Accord Healthcare

Accord Healthcare has submitted an Abbreviated New Drug Application (ANDA) for Dalfampridine, currently under standard review.

ClinicalJuly 1, 2026

Novartis initiates Phase I/II study of YTB323 in non-active Progressive Multiple Sclerosis

Novartis is conducting an open-label Phase I/II study to evaluate YTB323 in patients with non-active Progressive Multiple Sclerosis.

ClinicalJune 28, 2026

Study on Inflammatory Biomarkers for Diagnosing Multiple Sclerosis

An observational study aims to identify inflammatory biomarkers that could aid in the diagnosis of multiple sclerosis (MS) and differentiate it from other CNS autoimmune diseases.

RegulatoryJune 27, 2026

FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)

The FDA has approved a supplemental application for Copaxone, a treatment for multiple sclerosis.

StrategyJune 26, 2026

Innovative model for treatment sequencing in relapsing-remitting multiple sclerosis

A new computer-assisted model has been developed to optimize treatment sequencing for relapsing-remitting multiple sclerosis based on expert opinions.

ClinicalJune 20, 2026

Study on Corticosteroids for Healing Ring-Enhancing Lesions in Multiple Sclerosis

A clinical trial is investigating the efficacy of high-dose corticosteroids on ring-enhancing lesions in MS patients.

ClinicalJune 17, 2026

Phase 3 Trial of Orelabrutinib in Secondary Progressive MS Underway

A phase 3 trial is evaluating the efficacy and safety of orelabrutinib, CNS-penetrable BTK inhibitor, in patients with non-active Secondary Progressive MS.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.